Gastroparesis
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- Paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Gastroparesis
- Therapeutic area
- Gastroenterology
- gastroparesis
- gastroparalysis
- gastroparesis
- gastroparesis (disease)
- gastroparesis syndrome
- All therapeutic areas
- Gastroenterology
- Severity
- Moderate
- MONDO ID
- MONDO:0006769
- Parent condition
- MONDO:0001318
Related records
Broader conditions (6)
- Digestive system disorder
- Disease
- Disease by body system or component
- Functional gastric disease
- Human disease
- Stomach disorder
Narrower conditions (1)
Trials (288)
- 13C-Spirulina Nitrogen Content GEBT Study
- A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
- A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old
- A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
- A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
- A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis
- A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
- A Study of CNSA-001 in Women With Diabetic Gastroparesis
- A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
- A Study to Evaluate Safety and Effectiveness of G-POEM for Gastroparesis
- A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
- A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
- A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers
- A Study to Evaluate the Safety and Tolerability of Virtual Reality to Treat Gastroparesis
- A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
Approved drugs (1)
- Metoclopramide hydrochloride
Drugs in development (39)
- Aprepitant Phase 2
- Azithromycin Phase 2
- Buspirone Phase 2
- Camicinal Phase 2
- Deudomperidone Phase 2
- Dextrose Phase 2
- Docusate Phase 2
- Domperidone Phase 3
- Erythromycin Phase 2
- Felcisetrag Phase 2
- Granisetron Phase 2
- Itopride Phase 1
- Ketoconazole Phase 1
- Lisinopril anhydrous Phase 1
- Methylnaltrexone Phase 2
- Metoclopramide Phase 3
- Mitemcinal fumarate Phase 2
- Naronapride Phase 2
- Neostigmine Phase 2
- Nimacimab Phase 2
Other linked drugs (3)
- Botulinum toxin type A
- Sapropterin dihydrochloride
- Somatropin